Cancer BiologyCancer ResearchPeer-reviewed
A targetable PREX2/RAC1/PI3Kβ signalling axis confers resistance to clinically relevant therapeutic approaches in melanoma
Catriona A. Ford, Dana Koludrović, Patricia P. Centeno…·Andrew D. Campbell
This study identifies a druggable PREX2/RAC1/PI3Kβ signalling axis in BRAF-mutant melanoma that confers resistance to therapies and can be targeted to improve treatment outcomes.